Segall Bryant & Hamill LLC lowered its position in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) by 4.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,033 shares of the technology company’s stock after selling 5,315 shares during the quarter. Segall Bryant & Hamill LLC owned 0.29% of Novanta worth $12,169,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. Danske Bank A S bought a new position in shares of Novanta during the 3rd quarter valued at about $40,000. Allworth Financial LP boosted its holdings in Novanta by 978.4% during the fourth quarter. Allworth Financial LP now owns 399 shares of the technology company’s stock worth $47,000 after buying an additional 362 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Novanta by 120.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 427 shares of the technology company’s stock worth $51,000 after buying an additional 233 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Novanta in the fourth quarter valued at $53,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Novanta by 1,291.4% in the fourth quarter. Farther Finance Advisors LLC now owns 487 shares of the technology company’s stock valued at $58,000 after buying an additional 452 shares in the last quarter. 98.35% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Novanta
In other Novanta news, CEO Matthijs Glastra sold 6,500 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $161.13, for a total value of $1,047,345.00. Following the transaction, the chief executive officer owned 29,761 shares in the company, valued at $4,795,389.93. The trade was a 17.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on NOVT
Novanta Price Performance
Shares of NOVT opened at $142.55 on Monday. The business’s 50-day moving average is $154.33 and its 200-day moving average is $140.76. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.56 and a quick ratio of 2.69. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 103.30 and a beta of 1.68. Novanta Inc. has a fifty-two week low of $98.27 and a fifty-two week high of $171.85.
Novanta (NASDAQ:NOVT – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The technology company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.78 by $0.03. The business had revenue of $257.71 million during the quarter, compared to analysts’ expectations of $253.40 million. Novanta had a net margin of 5.35% and a return on equity of 12.06%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company posted $0.74 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. Equities research analysts expect that Novanta Inc. will post 3.59 EPS for the current fiscal year.
About Novanta
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
Featured Stories
- Five stocks we like better than Novanta
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
